Wall Street has issued downbeat forecasts for the stocks in this article. These predictions are rare - financial institutions ...

A senior scientist at the U.S. Centers for Disease Control and Prevention has resigned, warning that changes in leadership ...

The rise of the un-agency — Princeton10 and the future of pharma marketing. By registering you consent to the collection and use of your information to provide the products and services you have ...

TeamSense ranked all 50 states and the District of Columbia by their level of search interest in manufacturing topics.

Eli Lilly (NYSE: LLY) has been a growth beast over the years and is now easily the most valuable healthcare company in the world, with a market cap of more than $650 billion. But there's still ...

When an impressive opening act at the professional level and strong performances at the U23 camp string together, a first ...

May 27 (Reuters) - Eli Lilly (LLY.N), opens new tab will buy privately held SiteOne Therapeutics in a deal worth as much as $1 billion, the companies said on Tuesday, giving the drugmaker access ...

The head of drugmaker Eli Lilly, which sells the popular weight-loss drug Zepbound, urged the Trump administration to ease up on its tariff rollout because it could hurt Lilly’s business and the ...

Eli Lilly's growth is impressive, driven by Mounjaro and Zepbound, but its current valuation is only justifiable with sustained high growth. Despite strong results and superior products ...

Eli Lilly has been experiencing strong growth lately due to its impressive GLP-1 drugs. It could rake in a couple more approvals within the next year. The stock has been sliding this year ...